Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apollomics Inc Cl A (APLM)

Apollomics Inc Cl A (APLM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,696
  • Shares Outstanding, K 1,103
  • Annual Sales, $ 1,490 K
  • Annual Income, $ -53,860 K
  • EBIT $ 0 M
  • EBITDA $ -40 M
  • 60-Month Beta 1.82
  • Price/Sales 9.01
  • Price/Cash Flow N/A
  • Price/Book 2.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.01 +41.72%
on 10/30/25
42.12 -66.33%
on 10/15/25
-4.25 (-23.07%)
since 09/17/25
3-Month
3.66 +287.54%
on 08/29/25
42.12 -66.33%
on 10/15/25
+8.60 (+153.99%)
since 08/07/25
52-Week
3.66 +287.54%
on 08/29/25
42.12 -66.33%
on 10/15/25
+1.47 (+11.57%)
since 11/07/24

Most Recent Stories

More News
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing...

APLM : 14.18 (+6.46%)
APLMW : 0.0223 (+12.06%)
Nasdaq Resumes Trading in Apollomics Inc.

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq:...

NDAQ : 87.24 (+1.22%)
APLM : 14.18 (+6.46%)
Apollomics, Inc. Company Operational Continuity Update

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics...

APLM : 14.18 (+6.46%)
APLMW : 0.0223 (+12.06%)
Small Caps Shine Following Fed’s First Rate Cut in 9 Months

The Federal Reserve delivered its first rate cut in nine months, and small-cap stocks wasted no time celebrating. While the S&P 500 (SPX) dipped modestly and the Russell 3000 Index (RUA) closed near even,...

IPM : 1.9400 (+1.04%)
MNPR : 80.95 (+0.24%)
SPRC : 2.75 (+3.00%)
BGM : 9.70 (+5.43%)
BLDP : 3.50 (-1.41%)
IWV : 380.80 (+0.12%)
SQFT : 4.86 (-13.21%)
APLM : 14.18 (+6.46%)
GV : 1.4700 (+1.38%)
TVRD : 4.02 (+2.03%)
THH : 8.15 (-2.28%)
WFC : 86.04 (+0.53%)
Nasdaq Halts Apollomics Inc., Ltd.

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional...

NDAQ : 87.24 (+1.22%)
APLM : 14.18 (+6.46%)
APLMW : 0.0223 (+12.06%)
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

APLM : 14.18 (+6.46%)
APLMW : 0.0223 (+12.06%)
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

APLM : 14.18 (+6.46%)
APLMW : 0.0223 (+12.06%)
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

APLM : 14.18 (+6.46%)
APLMW : 0.0223 (+12.06%)
Apollomics Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Inc. has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing of its shares.Quiver AI SummaryApollomics Inc., a clinical-stage biopharmaceutical company...

APLM : 14.18 (+6.46%)
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

APLM : 14.18 (+6.46%)
APLMW : 0.0223 (+12.06%)

Business Summary

Apollomics Inc. is a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers. Apollomics Inc., formerly known as Maxpro Capital Acquisition Corp., is based in FOSTER CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 17.70
2nd Resistance Point 16.33
1st Resistance Point 15.25
Last Price 14.18
1st Support Level 12.80
2nd Support Level 11.43
3rd Support Level 10.35

See More

52-Week High 42.12
Fibonacci 61.8% 27.43
Fibonacci 50% 22.89
Fibonacci 38.2% 18.35
Last Price 14.18
52-Week Low 3.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar